Compound: Telmisartan
SMILES: O=C(O)c1c(-c2ccc(Cn3c4c(c(cc(c4)-c5nc6ccccc6n5C)C)nc3CCC)cc2)cccc1
InChIKey: RMMXLENWKUUMAY-UHFFFAOYSA-N
Synonyms: Telmisartan, 144701-48-4, Micardis, Pritor, Kinzalmono, BIBR 277, Semintra, BIBR-277, tolura, Telmisartan Teva, Telmisartan Actavis, BIBR-277-SE, BIBR-277SE, BIBR 277 SE, [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-, 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid, U5SYW473RQ, BIBR-277 SE, DTXSID8023636, C09CA07, 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid, 4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid, TELMISARTAN TEVA PHARMA, 2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid, CHEBI:9434, DTXCID803636, ONDUARP COMPONENT TELMISARTAN, TOLUCOMBI COMPONENT TELMISARTAN, KINZALKOMB COMPONENT TELMISARTAN, PRITORPLUS COMPONENT TELMISARTAN, (1,1'-Biphenyl)-2-carboxylic acid, 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-, MICARDISPLUS COMPONENT TELMISARTAN, 4'-[(1,4'-dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid, 2-(4-{[4-methyl-6-(1-methyl-1H-1,3-benzodiazol-2-yl)-2-propyl-1H-1,3-benzodiazol-1-yl]methyl}phenyl)benzoic acid, 4'-[[4-METHYL-6-(1-METHYL-2-BENZIMIDAZOLYL)-2-PROPYL-1-BENZIMIDAZOLYL]METHYL]-2-BIPHENYLCARBOXYLIC ACID, telmisartanum, 2-(4-((4-methyl-6-(1-methyl-1H-1,3-benzodiazol-2-yl)-2-propyl-1H-1,3-benzodiazol-1-yl)methyl)phenyl)benzoic acid, 2-(4-((4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl)methyl)phenyl)benzoic acid, 4'-((1,4'-dimethyl-2'propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid, 4'-((1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl)biphenyl-2-carboxylic acid, 4'-((4-Methyl-6-(1-methyl-1H-benzimidazol-2-yl)-2-propyl-1H-benzimidazol-1-yl)methyl)biphenyl-2-carboxylic acid, 4'-[[4-Methyl-6-(1-methyl-1H-benzimidazol-2-yl)-2-propyl-1H-benzimidazol-1-yl]methyl]biphenyl-2-carboxylic Acid, RefChem:6287, 620-494-7, 4'-((1,7'-Dimethyl-2'-propyl-1H,3'H-[2,5'-bibenzo[d]imidazol]-3'-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid, BIBR 277SE, Telmisartan [INN], C33H30N4O2, MFCD00918125, CHEMBL1017, 4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1h-benzimidazol]-1'-yl)methyl][1,1'-biphenyl]-2-carboxylic acid, NCGC00095150-01, Targit, 2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propyl-benzimidazol-1-yl]methyl]phenyl]benzoic acid, 4'[(1,4'-DIMETHYL-2'-PROPYL[2,6'-BI-1H-BENZIMIDAZOL]-1'-YL)METHYL][1,1'-BIPHENYL]-2-CARBOXYLIC ACID, Kinzal, Tazlok, Kinzal/Pritor, Micardis (TN), 4'-(1,7'-DIMETHYL-2'-PROPYL-1H-[2,5']BIBENZOIMIDAZOLYL-3'-YLMETHYL)-BIPHENYL-2-CARBOXYLIC ACID, SMR000466326, CAS-144701-48-4, Bay 68-9291, SR-01000759355, UNII-U5SYW473RQ, Telmisartana, Telmisartar, Telmisatran, BIBR277, Telsite, Telday, Telmisartan CRS, Kinzal;, Pritor;, HSDB 7590, Telma;, Teleact D;, Telmisartan [USAN:USP:INN:BAN], YM-086, BAY68-9291, Telmisartan (Micardis), Telmisartan (Standard), CPD000466326, TELMISARTAN [MI], Spectrum2_001976, Spectrum3_001089, Spectrum4_001261, Spectrum5_001053, TELMISARTAN [JAN], TELMISARTAN [HSDB], TELMISARTAN [USAN], TELMISARTAN [VANDF], SCHEMBL4464, TELMISARTAN [MART.], BSPBio_002738, GTPL592, KBioGR_001842, TELMISARTAN [USP-RS], TELMISARTAN [WHO-DD], MLS000759432, MLS001076687, MLS001424174, MLS006011851, Widaplik component Telmisartan, BIDD:GT0365, SPECTRUM1505261, SPBio_002131, TELMISARTAN [EMA EPAR], orb1308143, Telmisartan (JP17/USP/INN), SCHEMBL29356790, SCHEMBL29414101, SCHEMBL29691699, Telmisartan - Bio-X trade mark, TELMISARTAN [GREEN BOOK], KBio3_001958, TELMISARTAN [EP IMPURITY], TELMISARTAN [ORANGE BOOK], RMMXLENWKUUMAY-UHFFFAOYSA-N, Telmisartan for system suitability, GLXC-02564, HMS1922P07, HMS2051P16, HMS2090P17, HMS2093M22, HMS2231P07, HMS3393P16, HMS3655C08, HMS3715L17, HMS3750E19, HMS5079L20, Pharmakon1600-01505261, TELMISARTAN [EP MONOGRAPH], Telmisartan for peak identification, TELMISARTAN [USP MONOGRAPH], ALBB-028954, MSK10070, TWYNSTA COMPONENT TELMISARTAN, Tox21_111452, BBL029085, BDBM50043280, CCG-39514, DL-511, EBC-02079, HB2558, HY-13955R, NSC759811, s1738, STK624049, AKOS005557501, Telmisartan for system suitability CRS, Telmisartan, >=98% (HPLC), solid, Tox21_111452_1, AB07687, AC-2013, CS-1699, DB00966, FT15497, KS-1215, NC00296, NSC 759811, NSC-759811, Telmisartan for peak identification CRS, BAY-68-9291, MICARDIS HCT COMPONENT TELMISARTAN, NCGC00095150-02, NCGC00095150-03, NCGC00095150-04, NCGC00095150-06, NCGC00095150-07, NCGC00095150-08, TELMISARTAN [EMA EPAR VETERINARY], 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl][1,1'-biphenyl]-2-carboxylic acid, 4'-{[4-methyl-6-(1-methyl-1H-1,3-benzodiazol-2-yl)-2-propyl-1H-1,3-benzodiazol-1-yl]methyl}-[1,1'-biphenyl]-2-carboxylic acid, BT164444, HY-13955, SY052776, SBI-0206733.P001, NS00000398, SW197676-3, T2861, C07710, D00627, EN300-123532, AB00639941-06, AB00639941-07, AB00639941_08, AB00639941_09, L001035, Q733186, SR-01000759355-4, SR-01000759355-5, BRD-K73999723-001-02-2, BRD-K73999723-001-10-5, BRD-K73999723-001-11-3, Z1551967334, Telmisartan, European Pharmacopoeia (EP) Reference Standard, Telmisartan, United States Pharmacopeia (USP) Reference Standard, Telmisartan, Pharmaceutical Secondary Standard; Certified Reference Material, Telmisartan for peak identification, European Pharmacopoeia (EP) Reference Standard, Telmisartan for system suitability, European Pharmacopoeia (EP) Reference Standard, 2-(4-{[4-Methyl-6-(1-methyl-1H-1,3-benzodiazol-2-yl)-2-propyl-1H-1,3-benzodiazol-1-yl] methyl}phenyl)benzoic acid, 4''-((1,4''-dimethyl-2''-propyl(2,6''-bi-1H-benzimidazol)-1''-yl)methyl)-(1,1''-biphenyl)-2-carboxylic acid, 4''-((4-methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid, 4''-[(1,4''-dimethyl-2''propyl[2,6''-bi-1H-benzimidazol]-1''-yl)methyl]-[1,1''-biphenyl]-2-carboxylic acid, 4''-[(1,7''-dimethyl-2''-propyl-1H,3''H-2,5''-bibenzimidazol-3''-yl)methyl][1,1''-biphenyl]-2-carboxylic acid, 4''-[(1,7''-dimethyl-2''-propyl-1H,3''H-2,5''-bibenzimidazol-3''-yl)methyl]biphenyl-2-carboxylic acid, 4'-((1,7'-Dimethyl-2'-propyl-1H,3'H-[2,5'-bibenzo[d]imidazol]-3'-yl)methyl)-[1,1'-biphenyl]-2-carboxylicacid, 4'-((1,7'-DIMETHYL-2'-PROPYL-1H,3'H-2,5'-BIBENZO[D]IMIDAZOL-3'-YL)METHYL)BIPHENYL-2-CARBOXYLIC ACID, 4'-[(1,7'-Dimethyl-2'-propyl-1H,3'H-[2,5'-bi-1,3-benzimidazol]-3'-yl)methyl][1,1'-biphenyl]-2-carboxylic acid, 4'-[[2-n-Propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylic acid, 4'-[2-n-propyl-4-methyl-6-(1-methyl benzimidazol-2-yl)benzimidazol-1-yl methyl]biphenyl-2-carboxylic acid, TLS
Theoretical properties:
molecular_formula: C33H30N4O2
molecular_weight: 514.6 g/mol
exact_mass: 514.23687621 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 4
rotatable_bond_count: 7
heavy_atom_count: 39
topological_polar_surface_area: 72.9 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: White to slightly yellowish solid
color: White to slightly yellowish solid
melting_point: 261-263 °C
solubility: Practically insoluble
Descriptions:
pubchem: Telmisartan is a member of the class of benzimidazoles used widely in the treatment of hypertension. It has a role as an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor, an antihypertensive agent, a xenobiotic, an angiotensin receptor antagonist and an environmental contaminant. It is a carboxybiphenyl, a member of benzimidazoles and a member of biphenyls.
chebi: A member of the class of  benzimidazoles  used widely in the treatment of hypertension.
chembl: TELMISARTAN is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Telmisartan, sold under the brand name Micardis among others, is a medication used to treat high blood pressure and heart failure. It is a reasonable initial treatment for high blood pressure. It is taken by mouth.
Common side effects include upper respiratory tract infections, diarrhea, and back pain. Serious side effects may include kidney problems, low blood pressure, and angioedema. Use in pregnancy may harm the baby and use when breastfeeding is not recommended. It is an angiotensin II receptor blocker and works by blocking the effects of angiotensin II.
Telmisartan was patented in 1991 and came into medical use in 1999. It is available as a generic medication. In 2023, it was the 184th most commonly prescribed medication in the United States, with more than 2 million prescriptions. It is available in combination with hydrochlorothiazide as telmisartan/hydrochlorothiazide; with cilnidipine as telmisartan/cilnidipine; and with amlodipine as telmisartan/amlodipine.